Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

R0.6C transmission blocking vaccine

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Plasmodium falciparum transmission antigens

Phase 1 Most advanced trial (none active)
1 Registered trials

What is R0.6C transmission blocking vaccine?

R0.6C is a transmission blocking vaccine administered intramuscularly in four doses. It is designed to prevent malaria transmission by targeting Plasmodium falciparum antigens involved in parasite transmission.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Recombinant protein vaccine)
Targets
Plasmodium falciparum transmission antigens (antigen)
Mechanism
Immune activation, directed at Plasmodium falciparum transmission antigens
Therapy area
Infectious disease
In trials of
NVAX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04862416 Phase 1 Malaria Completed NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MalariaMalaria,Falciparum

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.